Blinatumomab, a Bispecific T-cell Engager (BiTE®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications

Min Zhu(Eye & ENT Hospital of Fudan University), Sameer Doshi(Amgen (United States)), Benjamin Wu(Amgen (United States)), Jessica Johnson(University of North Carolina at Chapel Hill), Andreas Wolf(Amgen (Germany)), Andrew Chow(Merck & Co., Inc., Rahway, NJ, USA (United States)), Christian Brandl(Amgen (Germany))
Clinical Pharmacokinetics
May 21, 2016
10.1007/s40262-016-0405-4
Cited by 213

Related Papers

De novo mutations in schizophrenia implicate synaptic networks
|Nature|2014|1.7k
Gene expression elucidates functional impact of polygenic risk for schizophrenia
|Nature Neuroscience|2016|1.2k
Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses
|Cell|2017|1.2k
Bone marrow CD169+ macrophages promote the retention of hematopoietic stem and progenitor cells in the mesenchymal stem cell niche
|The Journal of Experimental Medicine|2011|827
Regulation of tradeoffs between plant defenses against pathogens with different lifestyles
|Proceedings of the National Academy of Sciences|2007|735